Vítovec J, Spinar J
II. interní klinika FN U sv. Anny LF MU, Brno.
Vnitr Lek. 1998 Jun;44(6):336-41.
To assess the effect of ramipril on indicators of glucose metabolism, incl. insulin resistance, on renal function with microalbuminuria, changes of some echocardiographic signs of hypertrophy and compliance of the left ventricle in patients with hypertension and type II diabetes mellitus.
The authors examined 32 patients with hypertension grade I and II and with diabetes type II, who had ramipril, 2.5-10 mg/day, for a period of six months. The examination before and after long-term treatment comprised basic biochemical sampling incl. concentrations of immunoreactive insulin, C-peptide and glycated haemoglobin and also complete functional examination of the kidneys, incl. microalbuminuria. Echocardiographic examination was focused on assessment of signs of hypertrophy and compliance of the left ventricle. Treatment of diabetes was not changed in the course of 6 months.
In addition to the anticipated drop of blood pressure a declining trend of insulin resistance was recorded, there was a significant decline of microalbuminuria and a rise of natriuresis, the left ventricle mass declined and its compliance improved.
Ramipril one of the inhibitors of angiotensin converting enzyme is an effective and useful medication for type II diabetics suffering from hypertension.
评估雷米普利对高血压合并II型糖尿病患者糖代谢指标(包括胰岛素抵抗)、伴微量白蛋白尿的肾功能、左心室肥厚及顺应性的某些超声心动图征象变化的影响。
作者对32例I级和II级高血压合并II型糖尿病患者进行了研究,这些患者服用雷米普利,剂量为2.5 - 10毫克/天,为期6个月。长期治疗前后的检查包括基础生化取样,包括免疫反应性胰岛素、C肽和糖化血红蛋白的浓度,以及肾脏的全面功能检查,包括微量白蛋白尿。超声心动图检查重点是评估左心室肥厚和顺应性征象。在6个月的疗程中,糖尿病治疗方案未改变。
除预期的血压下降外,还记录到胰岛素抵抗呈下降趋势,微量白蛋白尿显著下降,钠尿增加,左心室质量下降,其顺应性改善。
雷米普利作为血管紧张素转换酶抑制剂之一,对患有高血压的II型糖尿病患者是一种有效且有用的药物。